- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07650448
WATER IV PCa (AS Sub-study)
WATER IV Prostate Cancer: Aquablation Versus Active Surveillance for the Treatment of Localized Prostate Cancer
The WATER IV study is a multicenter, prospective, randomized clinical trial that aims to evaluate the safety and efficacy of Aquablation therapy in men with localized prostate cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The WATER IV AS sub-study is a multicenter, prospective, randomized clinical trial that aims to evaluate the safety and efficacy of Aquablation therapy in men with low to intermediate risk localized prostate cancer who are candidates for active surveillance. Participants will be randomized to either Aquablation Therapy or active surveillance and followed up to 10 years.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Angela Lee
- Phone Number: 650-232-7215
- Email: a.lee@procept-biorobotics.com
Study Locations
-
-
-
Shatin, Hong Kong
- Not yet recruiting
- Chinese University of Hong Kong
-
Contact:
- Becky Lau
- Email: beckylau@surgery.cuhk.edu.hk
-
Principal Investigator:
- Jeremy Teoh, MD
-
-
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- Not yet recruiting
- Arizona State Urological Institute
-
Principal Investigator:
- Pratik Patel, MD
-
Contact:
- Dianna Baldanado
- Email: dbaldonado@asuri.net
-
-
California
-
Los Angeles, California, United States, 90089
- Recruiting
- University of Southern California
-
Principal Investigator:
- Inderbir Gill, MD
-
Principal Investigator:
- Mihir Desai, MD
-
Contact:
- Ileana Aldana
- Phone Number: (323) 865-0702
- Email: Nohely.Aldana@med.usc.edu
-
Murrieta, California, United States, 92562
- Not yet recruiting
- Tri Valley Urology
-
Contact:
- Anita Deeds
- Phone Number: 232 951-698-1901
- Email: anita@trivalleyurology.net
-
-
Colorado
-
Boulder, Colorado, United States, 80304
- Not yet recruiting
- Boulder Medical Center
-
Contact:
- Stephanie Leonard
- Email: sleonard@westernstatesncorp.org
-
-
Florida
-
Delray Beach, Florida, United States, 33484
- Recruiting
- Advanced Research
-
Principal Investigator:
- Christopher Tallman, MD
-
Contact:
- Julia Conceição
- Phone Number: (954)-302-3163
- Email: jconceicao@advancedresearchfl.com
-
Miami, Florida, United States, 33146
- Not yet recruiting
- University of Miami
-
Principal Investigator:
- Bruno Nahar, MD
-
Contact:
- Laura Ochoa
- Email: lxo315@med.miami.edu
-
Tampa, Florida, United States, 33607
- Not yet recruiting
- Trophy Point Urology
-
Contact:
- Zachary Finley
- Email: zfinley@floridaurologypartners.com
-
Principal Investigator:
- Timothy Weber, MD
-
Sub-Investigator:
- Jonathan Pavlinec, MD
-
Sub-Investigator:
- David Hochberg, MD
-
Sub-Investigator:
- Drew Palmer, MD
-
Sub-Investigator:
- Sam Fisher, MD
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
- Recruiting
- Georgia Urology
-
Principal Investigator:
- Lewis Kriteman, MD
-
Contact:
- Cyprian Adi
- Phone Number: 404-292-3727
- Email: Cyprian.adi@gaurology.com
-
Sub-Investigator:
- Froylan Gonzalez, MD
-
-
Idaho
-
Idaho Falls, Idaho, United States, 83401
- Recruiting
- Mountain View Hospital
-
Contact:
- Morgann Torres
- Email: mtorres1@mvhospital.net
-
Principal Investigator:
- Jared Manwaring, MD
-
Sub-Investigator:
- Richard Blatter, MD
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Not yet recruiting
- University of Chicago
-
Contact:
- Briana Harrison
- Email: bharrison1@bsd.uchicago.edu
-
Glenview, Illinois, United States, 60026
- Recruiting
- Endeavor Health
-
Sub-Investigator:
- Alexander Glaser, MD
-
Contact:
- Pooja Talaty
- Email: pooja.talaty@endeavorhealth.org
-
Principal Investigator:
- James Kearns, MD
-
Sub-Investigator:
- Brian Helfand, MD
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Not yet recruiting
- Johns Hopkins University
-
Principal Investigator:
- Arun Rai, MD
-
Contact:
- George Metri
- Email: gmetri1@jh.edu
-
Sub-Investigator:
- Arvin George, MD
-
-
Missouri
-
North Kansas City, Missouri, United States, 64116
- Not yet recruiting
- Kansas City Urology Care
-
Contact:
- Judy Searcy
- Phone Number: 913-647-4173
- Email: jsearcy@kcuc.com
-
Principal Investigator:
- Gerald Park, MD
-
Sub-Investigator:
- Patrick Probst, MD
-
-
Nebraska
-
Kearney, Nebraska, United States, 68847
- Recruiting
- Kearney Urology Center
-
Principal Investigator:
- Garrett Pohlman, MD
-
Contact:
- Monique Pohlman
- Email: water4trialkearneyurology@gmail.com
-
Omaha, Nebraska, United States, 68114
- Recruiting
- Adult & Pediatric Urology
-
Principal Investigator:
- Andrew Trainer, MD
-
Contact:
- Christian Valverde
- Email: cvalverde@urohealthpartners.com
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Not yet recruiting
- Hackensack University Medical Center
-
Principal Investigator:
- Nitin Yerram, MD
-
Contact:
- Oncology Clinical Research Referral Office
- Phone Number: 551-996-1777
- Email: OncologyResearchReferral@hmhn.org
-
Sub-Investigator:
- Ravi Munver, MD
-
-
New York
-
Albany, New York, United States, 12208
- Not yet recruiting
- Albany Medical College
-
Principal Investigator:
- Ronald Kaufman, MD
-
Contact:
- Brenda Romeo
- Phone Number: (518) 262-8579
-
New York, New York, United States, 10016
- Recruiting
- Integrated Medical Professionals, PLLC
-
Principal Investigator:
- Jed Kaminetsky, MD
-
Principal Investigator:
- Alexander Epelbaum, MD
-
Principal Investigator:
- Gary Goldberg, MD
-
Contact:
- Michael Yang
- Email: myang@imppllc.com
-
Rochester, New York, United States, 14642
- Not yet recruiting
- University of Rochester Medical Center
-
Contact:
- Caitlyn Michelsen
- Email: Caitlyn_Michelsen@URMC.Rochester.edu
-
Principal Investigator:
- Thomas Frye, MD
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Not yet recruiting
- Cleveland Clinic Foundation
-
Principal Investigator:
- Petar Bajic, MD
-
Contact:
- Lauren Grimm
- Phone Number: 216-444-4650
- Email: grimml@ccf.org
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Recruiting
- MUSC Hollings Cancer Center
-
Principal Investigator:
- Eric Wallen, MD
-
Contact:
- Sarah Helpinstill
- Phone Number: 843-792-9300
- Email: sah277@musc.edu
-
Murrells Inlet, South Carolina, United States, 29576
- Not yet recruiting
- Tidelands Health Urology
-
Contact:
- Barbara Roe
- Email: broe@tidelandshealth.org
-
Principal Investigator:
- Lauren Cooley, MD
-
-
Texas
-
Austin, Texas, United States, 78745
- Recruiting
- Urology Austin
-
Principal Investigator:
- Brian Mazzarella, MD
-
Contact:
- Jennifer Penshorn, RN
- Email: jennifer.penshorn@urologyaustin.com
-
Sub-Investigator:
- David Cuellar, MD
-
Sub-Investigator:
- Eric Giesler, MD
-
Sub-Investigator:
- Varun Sundaram, MD
-
Sub-Investigator:
- Carl Bischoff, MD
-
Austin, Texas, United States, 78705
- Recruiting
- Midtown Urology
-
Contact:
- Andrew Barger
- Phone Number: 512-451-7935
- Email: APBarger@cimplify.net
-
Principal Investigator:
- Michael Trotter, MD
-
Sub-Investigator:
- Tyler McClintock, MD
-
Dallas, Texas, United States, 75231
- Recruiting
- Urology Clinics of North Texas
-
Principal Investigator:
- Gregory Thoreson, MD
-
Contact:
- Jacquelyn Ward
- Email: jward@urologyclinics.com
-
-
Virginia
-
Alexandria, Virginia, United States, 22311
- Not yet recruiting
- Potomac Urology
-
Principal Investigator:
- Shawn Marhamati, MD
-
Sub-Investigator:
- Nilay Gandhi, MD
-
Contact:
- Zoe Goldstein
- Email: zoe.goldstein@potomacurology.com
-
-
Wisconsin
-
Sheboygan, Wisconsin, United States, 53081
- Not yet recruiting
- Advocate Aurora Research Institute
-
Principal Investigator:
- Jeffrey Tomasini, MD
-
Contact:
- Mary Theodoroff
- Email: mary.theodoroff@aah.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Biological male with age ≥ 45 years at the time of consent
- Biopsy positive Grade Group 2 prostate cancer or biopsy positive Grade Group 1 MRI visible lesion (PI-RADS/Likert ≥ 3)
- First prostate cancer diagnoses within 18 months (545 days) of consent
- Are candidates for active surveillance
- Clinical Stage ≤ T2c
- PSA < 15 ng/ml
- Prostate volume ≥25 ml
Exclusion Criteria:
- Any prior or current local or systemic treatment for prostate cancer, including but not limited to surgery, radiation therapy (external or brachytherapy), tissue ablation, hormone therapy or chemotherapy.
- Patients with previous surgical or minimally invasive treatment of benign prostatic hyperplasia within the prior 3 months of study treatment.
- Evidence of lymph node, bone metastasis, extracapsular extension or seminal vesicle invasion.
- Patient is unwilling to accept a blood transfusion if required.
- Any condition or history of illness or surgery that may pose an additional risk to patients undergoing the Aquablation or radical prostatectomy procedure such as:
5a. Medical conditions that preclude the use of anesthesia; 5b. Any condition or history of active rectal inflammatory bowel disease or other factors which might increase the risk of rectal injury (i.e. fistula formation); 5c. Patient is unable to stop anticoagulants or antiplatelet agents prior to study treatment per standard of care; 5d. Any other condition or history of infection, illness or surgery that in the opinion of the investigator might affect the outcome of the study procedure, study conduct, and study results; or pose additional risks to the patient (e.g., other cancer, active urethral stricture disease).
6. Patients who are unable to provide informed consent due to cognitive impairment, legal status (such as incarceration), or other factors limiting autonomy or unwilling or unable to follow study instructions including randomization and complete all required study visits through 10 years. This includes individuals with severe cognitive disabilities, those under legal guardianship, or those currently incarcerated.
7. Patient currently participating in other studies unless approved by Sponsor in writing.
8. More than one complete biopsy beyond the diagnostic biopsy comprising both a systematic biopsy and biopsy of any MRI visible lesion (PI-RADS/Likert ≥ 3).
9. GG2 disease with PSA ≥ 10 OR stage ≥ T2b OR ≥ 50% of biopsy cores positive (multiple cores taken from any MRI visible lesion are counted as one continuous core).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Aquablation Therapy
The Aquablation Therapy arm will receive Aquablation with either the AQUABEAM Robotic System or HYDROS Robotic System |
The AquaBeam Robotic System and the HYDROS Robotic System utilize high-velocity sterile saline waterjet to resect prostate tissue, guided by real-time visualization through cystoscopy and transrectal ultrasound imaging. This minimally invasive surgical procedure is called the Aquablation therapy. |
|
Active Comparator: Active Surveillance
The active surveillance arm will receive standard-of-care for prostate cancer management. |
Active surveillance is a management strategy for men with low- and favorable intermediate-risk localized prostate cancer that involves close monitoring with curative intent, reserving treatment for evidence of disease progression. Monitoring typically includes serial PSA testing, periodic prostate MRI, and repeat biopsies at scheduled intervals, with intervention triggered by evidence of disease progression. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Freedom from GG ≥ 2
Time Frame: 12 Months
|
12 Months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Freedom from persistent or increased MRI suspicion AND additional prostate cancer treatment
Time Frame: 3 Years
|
3 Years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Genital Neoplasms, Male
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Genital Diseases, Male
- Prostatic Diseases
- Male Urogenital Diseases
- Prostatic Neoplasms
- Health Services Administration
- Quality of Health Care
- Outcome Assessment, Health Care
- Outcome and Process Assessment, Health Care
- Watchful Waiting
Other Study ID Numbers
- CSP0005 - AS Sub-study
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.